CVM Funding Opportunities by mikeholy


									                                  CVM Funding Opportunities
                                              February 11, 2011

                                       Limited Submission Dates

Upcoming Limited Submission Program Internal Deadlines

March 31, 2011      Instrument Development for Biological Research (IDBR)           National Science Foundation

                      Construction                        Jan 25, May 25, Sept 25
                       R01, U01      New                  Feb 5, June 5, Oct 5
                          R01        Resubmit             March 5, July 5, Nov 5
                        R03,R21      New                  Feb 16, June 16, Oct 16
                          R21        Resubmit             March 16, July 16, Nov 16
                          R15                             Feb 25, June 25, Oct 25


Outstanding laboratory staff members contribute to university research mission – (Barbara Dryman/Carolyn

Abstracts invited for Carilion Clinic 2011 Research Day

Applications to 2011 ISCE Summer Scholars Program due February 15, 2011

(GSA) Research Symposium will be Wednesday, March 23rd, from 8am-4pm, in the Graduate Life Center
(GLC). Please use the link below to sign up to judge and/or to recruit colleagues to judge:
                                               Funding Opportunities

Title:      Extension Integrated Pest Management - Coordination and Support

Sponsor:    U.S. Department of Agriculture

Deadline:   March 29, 2011

            The primary elements of state extension IPM programs since inception have been to provide:
            • A focal point for IPM team building, communication and stakeholder participation;
            • Applied research and demonstration;
Abstract:   • Development of predictive models and information management systems;
            • Preparation of manuals and fact sheets;
            • Training programs for agents, consultants, scouts, growers, others; and
            • Technical assistance and trouble shooting.


Title:      Dialysis Like Therapeutics (DLT)

Sponsor:    Department of Defense

Deadline:   April 1, 2011

            Combat wound infection and the overwhelming blood infection called sepsis are significant problems for
            U.S. military personnel. Wound infections frequently lead to sepsis as clinicians diagnose infections
            primarily based on observable changes in sight, smell, body temperature, and blood pressure detected
            during an intermittent examination. Sepsis is an aggressive, non-discriminatory syndrome that can lead to
            loss of limbs, organ dysfunction, and ultimately death. Diagnosis of sepsis includes daily culture or
            molecular analysis of a small volume of the patient’s blood, typically less than 0.1% of the entire blood
            volume. Such detection methods are slow and fail to identify the pathogen in up to 50% of septic patients.
            Even if detected, there is no effective, non-specific method of removing pathogens and toxins from a
            patient’s blood. Instead, sepsis is typically treated with protocol-based broad spectrum antibiotics that
            frequently are not effective against the infecting pathogen. Frequent use of poorly targeted, broad
            spectrum antibiotics also encourages development of antibiotic-resistant bacteria. Antibiotic-resistant
            bacteria are an increasing problem for our injured warfighters and military treatment facilities. Bioagents
            engineered for resistance against antibiotics also represent a significant threat to our warfighters and
            As pathogen load is strongly correlated with patient morbidity and mortality, early detection and rapid
            reduction in pathogen load is considered fundamental to program success and eventual clinical impact.
            Even with state of the art supportive care and antibiotic administration, the mortality rate for sepsis is
            approximately 30% in the 5 civilian population, increasing in patients with military relevant conditions such
            as trauma, burns, or recent surgery.

            Past sepsis research has primarily focused on improved identification and pharmacologic modulation of
            various targets such as common pathogens, inflammatory biomolecules, and toxins. Unfortunately,
            discovery of pathogen molecular “labels”, sepsis biomarkers, inflammatory modulators, and new
            antibiotics has had minimal impact on the morbidity and mortality of sepsis. This program will develop
            innovative approaches to sepsis that advance beyond limitations in diagnosis and protocol-based
            pharmacologic treatment. Research that results in evolutionary improvements in prior research will be
            considered unresponsive to this announcement.

            2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of
            Addiction (DP1) RFA-DA-11-009

Sponsor:    National Institutes of Health

Deadline:   June 27, 2011

            The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or
            clinical researchers with the vision, drive and expertise necessary to translate research discoveries into
            medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute
            on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and
            efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine,
            methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals
            (“small molecules”) or biologics. Biologics include medicinal products such as vaccines and recombinant
            therapeutic proteins created by biological processes. Applications may focus on the pharma cotherapy of
Abstract:   one or various disorders. Applications may also focus on the specific symptoms of the disorder such as
            withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available
            for other indications, or new combinations of existing medications, which may be promising candidates
            for the treatment of diseases of addiction is within the scope of this FOA. The 2011 Translational Avant -
            Garde Award competition will proceed in two phases. The first phase is a pre -application phase in
            response to PAR-11-102. Applications will be evaluated by a group of external reviewers. Those
            investigators whose submissions are judged to be the most outstanding will be notified by April 26 of the
            opportunity to submit full applications under this FOA (DP1). The 2011 Avant -Garde awardees will be
            selected from this group of applicants.


Title:      Predictive Animal Models for Smoking Cessation Medications (U54) RFA-DA-11-014

Sponsor:    National Institutes of Health

            March 1, 2011 – letter of intent
            March 31, 2011 – application

            his FOA, issued by the National Institute on Drug Abuse, National Institutes of Health, solicits grant
            applications for a multi-project research program to develop a weighted battery of animal behavioral
            tests for preclinical development of smoking cessation medications.

            This research program seeks to significantly improve the predictive validity of in vivo screening of drug
            candidates. Since people smoke for many different reasons - withdrawal relief, pleasure, taste,
            improvement in concentration, weight control, stress control, irritability reduction, etc. - one approach
            to generating predictive models is to assess effects of effective anti-smoking pharmacotherapies on
Abstract:   specific components of tobacco dependence. Applications are expected to include animal behavior
            tests only. The critical part of this initiative is the establishment of a biostatistical/computational
            modeling core and individual project nodes, arranged according to behavioral paradigms being
            studied. The behavioral assessments used to model various domains of tobacco dependence should
            capture essential features of these processes. Funding would be provided through a cooperative
            center agreement mechanism (U54). Applications will be solicited for centers that include core and
            node activities. Applicants are responsible for arranging the agreements between different laboratories
            which will service all centers’ activities, including the statistical/administrative core as well as the
            behavioral nodes activities.

            Maximizing the Scientific Value of the NHLBI Biologic Specimen Repository: Scientific
            Opportunities (R21) RFA-HL-12-004

Sponsor:    National Institutes of Health

            April 4, 2011 letter of intent
            May 4, 2011 application

            This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and
            Blood Institute, solicits Exploratory/ Developmental Grant (R21) applications from
Abstract:   Investigators at institutions/organizations that propose to conduct research in heart, lung, and
            blood diseases, and blood resources using existing biospecimens stored in the NHLBI
            Biologic Specimen Repository (Biorepository).


Title:      Ancillary Studies to the NIDDK Intestinal Stem Cell Consortium (R01) PAR-11-07

Sponsor:    National Institutes of Health

Deadline:   June 5, 2010

            This FOA is to encourage Research Project Grant (R01) applications to conduct ancillary
            studies to the NIDDK Intestinal Stem Cell Consortium (ISCC). Studies will make use of
            consortium collaborations, techniques, and resources to accelerate research into intestinal
            stem cells. The proposed ancillary study must be designed to advance the scientific research
            mission of the NIDDK by focusing on diseases and areas of interest to the Institute and
            commensurate with the interests and intent of the ISCC.


Title:      Program Grants

Sponsor:    Human Frontier Science Program

Deadline:   March 31, 2011 letter of intent (register by March 22)

            The Human Frontier Science Program (HFSP) supports innovative basic research into fundamental
            biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific
            exchanges across national and disciplinary boundaries. In the past decade biological research has
            become increasingly quantitative rather than descriptive. The participation of scientists from disciplines
            outside the traditional life sciences such as biophysics, chemistry, computational biology, computer
            science, engineering, mathematics, nanoscience or physics has contributed to this change and will
            continue to do so. Such collaborations have opened up new approaches for understanding the complex
Abstract:   structures and regulatory networks that characterize living organisms, their evolution and interactions.

            To stimulate novel, daring ideas and innovative approaches, preliminary results are not required
            in research grant applications. The HFSP places special emphasis on encouraging scientists early in
            their careers – this is expressed both in the establishment of a special Young Investigators‟ Grant and in
            encouraging scientists early in their careers to participate in the Program Grants. Applicants are expected
            to develop new lines of research through the collaboration.

Title:      Grand Challenges: Biomarkers Grant Opportunity

Sponsor:    The Bill & Melinda Gates Foundation

Deadline:   March 31, 2011 letter of inquiry

            The goal of this program is to test biomarkers to enable characterization and validation of markers for
            diagnosing tuberculosis (TB). Projects that will be considered for funding will investigate specific
            biomarkers for which there exists a preliminary base of evidence, but for which additional data is required
            to determine utility for diagnosis. This can include biomarkers where the hypothesis derives from novel
Abstract:   biological concepts in pathogen (Mycobacterium tuberculosis) or host biology, and/or promising methods
            or concepts from other research areas applied to TB using a rational approach. For the purposes of this
            program, we will only consider the investigation of biomarkers for which there is a clear hypothesis that
            measurement or detection of the specific biomarker is linked to the presence of TB; we will not consider
            unbiased biomarker discovery efforts.



            American College of Veterinary Dermatology
            American Academy of Veterinary Dermatology

Deadline:   December 1, 2011

            Research grants will be awarded by the ACVD and AAVD for basic and clinical research in veterinary
            dermatology. Total amount of funding available for each grant is up to $30,000.00. The precise amount to
            be awarded will depend on the amount collected by the research fund each year. The group will award at
            least one basic science and one clinical grant. Applicants will be expected to propose a project of
            scientific merit that is applicable to veterinary dermatology. The proposal should describe the feasibility of
            completing the project within one year of the award and within the proposed budget.


To top